English
Home > Products > CAS NO 402-67-5

China CAS NO 402-67-5 Factory

Our enterprise since its inception, constantly regards product good quality as organization life, constantly improve production technology, strengthen merchandise high quality and continuously strengthen enterprise total good quality administration, in strict accordance with all the national standard ISO 9001:2000 for CAS NO 402-67-5,402-67-5,1-Fluoro-3-nitrobenzene, "Quality first, Price lowest, Service best" is the spirit of our company. We sincerely welcome you to visit our company and negotiate mutual business!
CAS NO 402-67-5, We aim to become the modern enterprise with the commercial ideal of "Sincerity and confidence" and with the aim of "Offering customers the most sincere services and best quality products". We sincerely ask for your unchanged support and appreciate your kind advice and guidance.

Related Products

Hot Products

  • 6-Methoxyguanine

    6-Methoxyguanine

    Product Name:6-Methoxyguanine
    Molecular Formula:C6H7N5O
    Molecular Weight:165.15
    CAS Registry Number:20535-83-5
  • Telmisartan

    Telmisartan

    Product Name:Telmisartan
    Molecular Formula:C33H30N4O2
    Molecular Weight;514.62
    CAS Registry Number;144701-48-4
  • (9R)-9-hydroxy-6,7,8,9-tetrahydrocyclohepta[b]pyridin-5-one

    (9R)-9-hydroxy-6,7,8,9-tetrahydrocyclohepta[b]pyridin-5-one

    Product Name:(9R)-9-hydroxy-6,7,8,9-tetrahydrocyclohepta[b]pyridin-5-one
    Molecular Formula:C10H11NO2
    Molecular Weight:177.2
    CAS Registry Number:1190363-44-0
  • 1-Chloro-6,6-dimethyl-5-hept-2-en-4-ino

    1-Chloro-6,6-dimethyl-5-hept-2-en-4-ino

    Product Name:1-Chloro-6,6-dimethyl-5-hept-2-en-4-ino
    Molecular Formula:C9H13Cl
    Molecular Weight:156.65
    CAS Registry Number:126764-17-8
  • 2,3,4-Trifluorotoluene

    2,3,4-Trifluorotoluene

    Product Name:2,3,4-Trifluorotoluene
    Molecular Formula:C7H5F3
    Molecular Weight:146.11
    CAS Registry Number:193533-92-5
  • Abrocitinib

    Abrocitinib

    Product Name:Abrocitinib
    Molecular Formula:C14H21N5O2S
    Molecular Weight;323.41
    CAS Registry Number;1622902-68-4
  • Related Blog
  • Reviews

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • What is an Active Pharmaceutical Ingredient (API in Pharma)?

    Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept